Login to Your Account

In The Clinic NEWS

A potential new tool in the war on gram-negative pathogens, The Medicines Co.’s Carbavance (meropenem-vaborbactam) met both FDA and EMA primary endpoints in a pivotal phase III trial testing the therapy in patients with complicated urinary tract infections (cUTIs).

TOKYO – Takeda Pharmaceutical Co. Ltd. said its TAK-214 vaccine, the world’s first to tackle the Norovirus, is now in phase IIb field efficacy trials.

SHANGHAI – A transdermal pain patch being studied by Frontier Biotechnologies Inc., of Nanjing, China, has met its primary endpoints in a U.S. phase II trial of 146 patients with chronic lower back pain.

More In The Clinic Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: